Results overview: Found 7 records in 0.02 seconds.
Articles, 7 records found
Articles 7 records found  
1.
14 p, 1.3 MB Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) / Gordon, Leo I. (Northwestern University Feinberg School of Medicine) ; Karmali, Reem (Northwestern University Feinberg School of Medicine) ; Kaplan, Jason B. (Northwestern University Feinberg School of Medicine) ; Popat, Rakesh (University College London) ; Burris, Howard A. (Sarah Cannon Research Institute/Tennessee Oncology) ; Ferrari, Silvia (Ospedale Papa Giovanni XXIII) ; Madan, Sumit (Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA) ; Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ; Gritti, Giuseppe (Ospedale Papa Giovanni XXIII) ; El-Sharkawi, Dima (Royal Marsden Hospital (Regne Unit)) ; Chau, F. Ian (Royal Marsden Hospital (Regne Unit)) ; Radford, John (University of Manchester) ; de Oteyza, Jaime Pérez (Hospital Universitario HM Sanchinarro (Madrid)) ; Zinzani, Pier Luigi (Università di Bologna) ; Iyer, Swaminathan P. (University of Texas MD Anderson Cancer Center) ; Townsend, William (University College London Hospitals) ; Miao, Harry (Takeda Development Center Americas) ; Proscurshim, Igor (Takeda Development Center Americas) ; Wang, Shining (Takeda Development Center Americas) ; Katyayan, Shilpi (Labcorp Drug Development (Estats Units d'Amèrica)) ; Yuan, Ying (Takeda Development Center Americas) ; Zhu, Jiaxi (Takeda Development Center Americas) ; Stumpo, Kate (Takeda Development Center Americas) ; Shou, Yaping (Takeda Development Center Americas) ; Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia) ; Bosch José, Francesc Xavier 1947- (Universitat Autònoma de Barcelona)
We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). [...]
2023 - 10.18632/oncotarget.28352
Oncotarget, Vol. 14 (january 2023) , p. 57-70  
2.
9 p, 1.7 MB KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust) ; Chau, Ian (The Royal Marsden NHS Foundation Trust) ; Cunningham, David (The Royal Marsden NHS Foundation Trust) ; Hahne, Jens Claus (The Institute of Cancer Research) ; Vlachogiannis, George (The Institute of Cancer Research) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust) ; Lampis, Andrea (The Institute of Cancer Research) ; Braconi, Chiara (The Institute of Cancer Research) ; Kalaitzaki, Eleftheria (The Royal Marsden NHS Foundation Trust) ; De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust) ; Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Glimelius, Bengt (University of Uppsala) ; Tarazona, Noelia (Universitat de València) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust) ; Lote, Hazel (The Institute of Cancer Research) ; Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust) ; Mentrasti, Giulia (The Institute of Cancer Research) ; Brown, Gina (The Royal Marsden NHS Foundation Trust) ; Tait, Diana (The Royal Marsden NHS Foundation Trust) ; Oates, Jacqueline (The Royal Marsden NHS Foundation Trust) ; Valeri, Nicola (The Institute of Cancer Research) ; Universitat Autònoma de Barcelona
There are limited data on circulating, cell-free, tumour (ct)DNA analysis in locally advanced rectal cancer (LARC). Digital droplet (dd)PCR was used to investigate KRAS/BRAF mutations in ctDNA from baseline blood samples of 97 LARC patients who were treated with CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX ± cetuximab in a randomised phase II trial. [...]
2018 - 10.1038/s41598-018-19212-5
Scientific reports, Vol. 8 (january 2018)  
3.
8 p, 196.5 KB Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer / Sclafani, Francesco (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Brown, Gina (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Cunningham, David (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Wotherspoon, Andrew (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Mendes, Larissa Sena Teixeira (Department of Histopathology, The Royal Marsden NHS Foundation Trust) ; Balyasnikova, Svetlana (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Evans, Jessica (Department of Radiology, The Royal Marsden NHS Foundation Trust) ; Peckitt, Clare (Clinical Research & Development, The Royal Marsden NHS Foundation Trust) ; Begum, Ruwaida (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tait, Diana (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Glimelius, Bengt (Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, University of Uppsala) ; Roselló, Susana (Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia) ; Thomas, Janet (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Oates, Jacqui (Department of Medicine, The Royal Marsden NHS Foundation Trust) ; Chau, Ian (Department of Medicine, The Royal Marsden NHS Foundation Trust)
Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). [...]
2017 - 10.1038/bjc.2017.320
British Journal of Cancer, Vol. 117 (09 2017) , p. 1478-1485  
4.
11 p, 388.8 KB Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab / Arnold, D. (Instituto CUF de Oncologia (I.C.O.), Lisboa) ; Fuchs, C. S. (Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA) ; Tabernero, Josep (Universitat Autònoma de Barcelona) ; Ohtsu, A. (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Zhu, A. X (Massachusetts General Hospital (Boston)) ; Garon, E. B. (Hematology Oncology, David Geffen School of Medicine at UCLA Translational Research in Oncology-US Network, Santa Monica, USA) ; Mackey, J. R. (Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada) ; Paz Ares, L. (Hospital Universitario 12 de Octubre (Madrid)) ; Baron, A. D. (Division of Hematology Oncology, California Pacific Medical Center, San Francisco, USA) ; Okusaka, T. (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan) ; Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan) ; Yoon, H. H. (Division of Medical Oncology, Mayo Clinic, Rochester, USA) ; Das, M. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Ferry, David (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Zhang, Y (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Lin, Y (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Binder, P. (Oncology, Eli Lilly and Company, Bridgewater, USA) ; Sashegyi, A.. (Oncology, Eli Lilly and Company, Indianapolis, USA) ; Chau, Ian (Department of Medicine, Royal Marsden Hospital, Sutton, UK)
Ramucirumab, the human immunoglobulin G1 monoclonal antibody receptor antagonist of vascular endothelial growth factor receptor 2, has been approved for treating gastric/gastroesophageal junction, non-small-cell lung, and metastatic colorectal cancers. [...]
2017 - 10.1093/annonc/mdx514
Annals of oncology, Vol. 28 (september 2017) , p. 2932-2942  
5.
9 p, 1.1 MB Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab / Fuchs, Charles S. (Harvard Medical School) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Tomášek, Jiří (Masaryk University (Czech Republic)) ; Chau, Ian (Royal Marsden Hospital (Regne Unit)) ; Melichar, Bohuslav (Univerzity Palackeho a Fakultni nemocnice (Czech Republic)) ; Safran, Howard (Brown University Oncology Research Group (USA)) ; Tehfe, Mustapha A. (Centre Hospitalier de Montréal (Canada)) ; Filip, Dumitru (Spitalul Judetean de Urgenta (Romania)) ; Topuzov, Eldar (Northwest State Medical University na II Mechnikov) ; Schlittler, Luis (Hospital da Cida de Passo Fundo (Brasil)) ; Udrea, Anghel Adrian (Medisprof SRL (Romania)) ; Campbell, William (Hospital Herrera Llerandi (Guatemala)) ; Brincat, Stephen (Sir Anthony Mamo Oncology Centre (Malta)) ; Emig, Michael (Lilly Deutschland GmbH (Germany)) ; Melemed, Symantha A. (Lilly Corporate Center (USA)) ; Hozak, Rebecca R. (Lilly Corporate Center (USA)) ; Ferry, David (Lilly Corporate Center (USA)) ; Caldwell, C. William (Lilly Corporate Center (USA)) ; Ajani, Jaffer A. (The University of Texas MD Anderson Cancer Center (USA)) ; Universitat Autònoma de Barcelona
Angiogenesis inhibition is an important strategy for cancer treatment. Ramucirumab, a human IgG1 monoclonal antibody that targets VEGF receptor 2 (VEGFR2), inhibits VEGF-A, -C, -D binding and endothelial cell proliferation. [...]
2016 - 10.1038/bjc.2016.293
British Journal of Cancer, Vol. 115, Issue 8 (October 2016) , p. 974-982  
6.
6 p, 1.4 MB Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Lampis, Andrea (The Institute of Cancer Research. Department of Molecular Pathology) ; Hahne, Jens Claus (The Institute of Cancer Research. Department of Molecular Pathology) ; Ghidini, Michele (The Institute of Cancer Research. Department of Molecular Pathology) ; Lote, Hazel (The Institute of Cancer Research. Department of Molecular Pathology) ; Zito, Domenico (The Institute of Cancer Research. Department of Molecular Pathology) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Glimelius, Bengt (University of Uppsala. Genetics and Pathology, Experimental and Clinical Oncology. Department of Immunology) ; Cervantes, Andrés (University of Valencia. Biomedical Research Institute INCLIVA. Department of Haematology and Medical Oncology) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; De Castro, David Gonzalez (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wilson, Sanna Hulkki (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Peckitt, Clare (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Tait, Diana (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Oates, Jacqueline (The Royal Marsden NHS Foundation Trust. Department of Medicine) ; Braconi, Chiara (The Institute of Cancer Research. Department of Cancer Therapeutics) ; Valeri, Nicola (The Institute of Cancer Research. Department of Molecular Pathology) ; Universitat Autònoma de Barcelona
Analysis of a polymorphism in mature microRNA-608 (rs4919510) in rectal cancer patients enrolled in a randomized phase II clinical trial identified patient subpopulations who might benefit from the use of an intensified neo-adjuvant treatment strategy with Cetuximab. [...]
2016 - 10.1093/carcin/bgw073
Carcinogenesis, Vol. 37 (july 2016) , p. 852-857  
7.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, Francesco (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, Ian (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, Andrea (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, Jens Claus (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, Chiara (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, Andrés (Universitat de València. Departament d'Hematologia i Oncologia Mèdica) ; Begum, Ruwaida (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; González De Castro, David (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, Sanna (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Zakaria (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, Andrew (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, Gina (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, Nicola (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  

See also: similar author names
6 Chau, Ian
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.